Intention-to-treat analysis keeps all trial data, showing true drug effects, even with dropouts. It contrasts with per-protocol analysis, where dropout data is excluded, possibly skewing results.
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Hemodynamic instability and myocardial dysfunction are major factors preventing the transplantation of hearts from organ donors after brain death. Intravenous levothyroxine is widely used in donor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback